EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+14.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.3B
AUM Growth
+$1.3B
(-0.24%)
Cap. Flow
-$181M
Cap. Flow
% of AUM
-13.88%
Top 10 Holdings %
Top 10 Hldgs %
62.01%
Holding
84
New
10
Increased
22
Reduced
31
Closed
17
Top Buys
| 1 |
GSK
GSK
|
$24.1M |
| 2 |
ZimVie
ZIMV
|
$20.7M |
| 3 |
Bausch Health
BHC
|
$12.5M |
| 4 |
Bio-Techne
TECH
|
$9.63M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$9.46M |
Top Sells
| 1 |
Inspire Medical Systems
INSP
|
$54.2M |
| 2 |
Natera
NTRA
|
$38.5M |
| 3 |
United Therapeutics
UTHR
|
$37.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$26.8M |
| 5 |
Novo Nordisk
NVO
|
$21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$14.3B
| $10.2M | 0.7% | 134,959 +19,139 | +17% | +$1.44M |
|
27
Elevance Health
ELV
$71.8B
| $10.1M | 0.69% | 19,465 +4,808 | +33% | +$2.5M |
|
28
Fortrea Holdings
FTRE
$894M
| $9.16M | 0.63% | +457,967 | New | +$9.16M |
|
|
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.11M | 0.62% | +124,491 | New | +$9.11M |
|
30
Evolus
EOLS
$494M
| $7.34M | 0.5% | 453,061 -121,401 | -21% | -$1.97M |
|
31
Biohaven
BHVN
$1.63B
| $6.62M | 0.45% | +132,537 | New | +$6.62M |
|
32
Arcutis Biotherapeutics
ARQT
$1.86B
| $6.45M | 0.44% | 693,263 -144,584 | -17% | -$1.34M |
|
33
Sutro Biopharma
STRO
$72.7M
| $6.37M | 0.44% | 1,841,989 +102,860 | +6% | +$356K |
|
34
Brookdale Senior Living
BKD
$1.83B
| $5.85M | 0.4% | 861,268 -685,574 | -44% | -$4.66M |
|
35
NewAmsterdam Pharma
NAMS
$2.71B
| $5.1M | 0.35% | 307,357 -22,533 | -7% | -$374K |
|
|
FNA
36
DELISTED
Paragon 28, Inc.
FNA
| $5M | 0.34% | +749,213 | New | +$5M |
|
37
Gossamer Bio
GOSS
$562M
| $4.91M | 0.34% | 4,978,458 -505,690 | -9% | -$499K |
|
|
TSVT
38
DELISTED
2seventy bio
TSVT
| $4.71M | 0.32% | 998,079 -109,664 | -10% | -$518K |
|
39
Karyopharm Therapeutics
KPTI
$61.7M
| $4.6M | 0.32% | 5,547,880 +560,700 | +11% | +$465K |
|
40
Avantor
AVTR
$9.18B
| $4.36M | 0.3% | 168,369 +42,975 | +34% | +$1.11M |
|
41
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.07M | 0.28% | 535,405 -617,168 | -54% | -$4.69M |
|
42
Icon
ICLR
$13.8B
| $3.93M | 0.27% | 13,668 +1,026 | +8% | +$295K |
|
43
Kura Oncology
KURA
$686M
| $3.76M | 0.26% | 192,398 +120,081 | +166% | +$2.35M |
|
44
Molina Healthcare
MOH
$9.8B
| $3.65M | 0.25% | 10,588 -7,689 | -42% | -$2.65M |
|
45
Merus
MRUS
$4.98B
| $3.41M | 0.23% | 68,258 +1,784 | +3% | +$89.1K |
|
46
STAAR Surgical
STAA
$1.36B
| $3.39M | 0.23% | +91,199 | New | +$3.39M |
|
47
Puma Biotechnology
PBYI
$254M
| $3.3M | 0.23% | 1,293,257 -35,197 | -3% | -$89.8K |
|
48
Zai Lab
ZLAB
$3.68B
| $3.26M | 0.22% | +135,219 | New | +$3.26M |
|
|
ZBIO
49
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $3.22M | 0.22% | +190,531 | New | +$3.22M |
|
|
MREO
50
Mereo BioPharma
MREO
$272M
| $3.2M | 0.22% | 777,890 +281,719 | +57% | +$1.16M |
|